From the Journals

Lymphocyte, monocyte data can predict treatment response in follicular lymphoma


 

FROM CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA

Absolute lymphocyte cell (ALC) and absolute monocyte cell (AMC) counts, as well as their ratio (LMR) proved to be prognostic factors for treatment results, as shown by a database analysis of follicular lymphoma (FL) patients.

Progressive disease and stable disease after first-line therapy, as well as the mortality rate, were significantly associated with lower ALC, higher AMC, and higher LMR, according to the report published online.

Researchers analyzed the data of 100 FL variant patients admitted and treated between January 2009 and June 2018 at a single center.

Area under the curve analysis for discriminating between survival times showed 0.57 x 109 cells/L was the most discriminative ALC cutoff value, 1.24 x 109/L was the most discriminative AMC cutoff value, and 1.63 x 109/L was the most discriminative LMR cutoff value.

Shorter overall survival (OS) was significantly associated with lower ALC, compared with those having higher ALC. Shorter OS and progression-free survival (PFS) were significantly associated with higher AMC, compared with those having lower AMC. Shorter OS and PFS were also significantly associated with lower LMR, compared with those having higher LMR.

Overall, a high-risk score in the Follicular Lymphoma International Prognostic Index (FLIPI) and having a low LMR were considered risk factors for prediction of OS in all the studied FL patients in univariate analysis and multivariate analysis, according to the researchers.

“Our results prove the effect of lymphocyte and monocyte in the tumor immune response, which gives opportunity to several therapeutic strategies that target myeloid-derived suppressor cells (MDSCs), including monocytes and their progeny and improves the T-cell function in eradication strategies,” the researchers concluded.

No study funding or disclosure details were provided.

SOURCE: Mohsen A et al. Clin Lymphoma Myeloma Leuk. 2020 Mar 20. doi: 10.1016/j.clml.2020.03.007.

Recommended Reading

Dr. Matt Kalaycio’s top 10 hematologic oncology abstracts for ASCO 2016
B-Cell Lymphoma ICYMI
Phase III trial: VZV protects auto-HCT patients
B-Cell Lymphoma ICYMI
Basiliximab/BEAM may improve post-ASCT outcomes in PTCL
B-Cell Lymphoma ICYMI
Best options for treating relapsed/refractory PTCL
B-Cell Lymphoma ICYMI
FDA places partial hold on trials after secondary lymphoma
B-Cell Lymphoma ICYMI
Make The Diagnosis - September 2018
B-Cell Lymphoma ICYMI
FDA lifts partial hold on tazemetostat trials
B-Cell Lymphoma ICYMI
ECHELON-2: BV-CHP boosts survival in PTCL
B-Cell Lymphoma ICYMI
Four-drug combo shows durable responses in relapsed/refractory lymphomas
B-Cell Lymphoma ICYMI